Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2002

Open Access 01-12-2002 | Research article

The average cost of measles cases and adverse events following vaccination in industrialised countries

Authors: Hélène Carabin, W John Edmunds, Ulla Kou, Susan van den Hof, Van Hung Nguyen

Published in: BMC Public Health | Issue 1/2002

Login to get access

Abstract

Background

Even though the annual incidence rate of measles has dramatically decreased in industrialised countries since the implementation of universal immunisation programmes, cases continue to occur in countries where endemic measles transmission has been interrupted and in countries where adequate levels of immunisation coverage have not been maintained. The objective of this study is to develop a model to estimate the average cost per measles case and per adverse event following measles immunisation using the Netherlands (NL), the United Kingdom (UK) and Canada as examples.

Methods

Parameter estimates were based on a review of the published literature. A decision tree was built to represent the complications associated with measles cases and adverse events following imminisation. Monte-Carlo Simulation techniques were used to account for uncertainty.

Results

From the perspective of society, we estimated the average cost per measles case to be US$276, US$307 and US$254 for the NL, the UK and Canada, respectively, and the average cost of adverse events following immunisation per vaccinee to be US$1.43, US$1.93 and US$1.51 for the NL, UK and Canada, respectively.

Conclusions

These average cost estimates could be combined with incidence estimates and costs of immunisation programmes to provide estimates of the cost of measles to industrialised countries. Such estimates could be used as a basis to estimate the potential economic gains of global measles eradication.
Appendix
Available only for authorised users
Literature
1.
De Serres G, Gay NJ, Farrington CP: Epidemiology of transmissible disease after elimination. Am J Epidemiol. 2000, 151: 1039-48.CrossRefPubMed
2.
Cronin M, Fitzsimmons GJ: Measles outbreak in the Republic of Ireland: update. Eurosurveillance Weekly. 2000, 4-
3.
Outbreak of measles in an army base in Germany. Eurosurveillance Weekly. 2001, 5-
4.
Measles outbreak, Netherlands. Wkly Epidemiol Rec. 2000, 75: 119-21.
5.
Measles outbreak – Netherlands, April 1999 – January 2000. MMWR Morb Mortal Wkly Rep. 2000, 49: 299-303.
6.
Clarkson JA, Fine PE: The efficiency of measles and pertussis notification in England and Wales. Int J Epidemiol. 1985, 14: 153-68.CrossRefPubMed
7.
8.
9.
McDonnell IF, Jorm LR: Measles epidemic in western Sydney. New South Wales Public Health Bulletin. 1994, 5: 59-60.CrossRef
10.
Miller DL: Frequency of complications of measles, 1963. Report on a National inquiry by the Public Health Laboratory Service in Collaboration with the society of medical officers of health. Br Med J. 1964, 2: 75-8.CrossRefPubMedPubMedCentral
11.
12.
Godoy P, Dominguez A, Alvarez J, et al: Measles epidemiology in Catalonia (Spain): implications for a regional vaccination programme. Int J Epidemiol. 1999, 28: 558-62. 10.1093/ije/28.3.558.CrossRefPubMed
13.
van den Hof S, van den Kerkhof JH, ten Ham PB, van Binnendijk RS, Conyn-van Spaendonck MA, van Steenbergen JE: [Measles epidemic in the Netherlands, 1999–2000]. Ned Tijdschr Geneesk. 2001, 145: 2529-33.
14.
Grimsrud K: Cases of measles in the Alberta's (Canada) outbreak. Personal Communication. 2001
15.
Godoy P, Dominguez A, Camps N, et al: [Validity of the notifications of red measles based on clinical diagnosis in Cataluna, Spain]. Enfermedades Infecciosas y Microbiologia Clinica. 1999, 17: 180-3.PubMed
16.
Dales LG, Kizer KW, Rutherford GW, Pertowski CA, Waterman SH, Woodford G: Measles epidemic from failure to immunize. West J Med. 1993, 159: 455-64.PubMedPubMedCentral
17.
Hanratty B, Holt T, Duffell E, et al: UK measles outbreak in non-immune anthroposophic communities: the implications for the elimination of measles from Europe. Epidemiol Infect. 2000, 125: 377-83. 10.1017/S0950268899004525.CrossRefPubMedPubMedCentral
18.
Mason WH, Ross LA, Lanson J, Wright HT: Epidemic measles in the postvaccine era: evaluation of epidemiology, clinical presentation and complications during an urban outbreak. Pediatr Infect Dis J. 1993, 12: 42-8.CrossRefPubMed
19.
Loras-Duclaux I, David L, Peyramond D, Floret D, Lachaux A, Hermier M: [Epidemiological study and cost evaluation of measles in Lyons hospitals over a 5-year period]. Pédiatrie. 1988, 43: 451-4.PubMed
20.
Shiell A, Jorm LR, Carruthers R, Fitzsimmons GJ: Cost-effectiveness of measles outbreak intervention strategies. Aust N Z J Public Health. 1998, 22: 126-32.CrossRefPubMed
21.
Farrington CP: Subacute sclerosing panencephalitis in England and Wales: transient effects and risk estimates. Stat Med. 1991, 10: 1733-44.CrossRefPubMed
22.
Madge N, Diamond J, Miller D, et al: The National Childhood Encephalopathy study: a 10-year follow-up. A report on the medical, social, behavioural and educational outcomes after serious, acute, neurological illness in early childhood. Dev Med Child Neurol. 1993, 35: 1-118.
23.
Hart YM, Shorvon SD: The nature of epilepsy in the general population. I. Characteristics of patients receiving medication fro epilepsy. Epilepsy Res. 1995, 21: 43-9. 10.1016/0920-1211(95)00007-W.CrossRefPubMed
24.
Carabin H, Gyorkos TW, Soto JC, Penrod J, Joseph L, Collet J-P: Estimation of direct and indirect costs due to common infections in toddlers attending daycare centres. Pediatrics. 1999, 103: 556-64.CrossRefPubMed
25.
Hastings A, Hostler A, Solen A: Measles: who pays the cost?. Br Med J (Clin Res Ed). 1987, 294: 1527-8.CrossRef
26.
Brisson M, Edmunds WJ: The cost-effectiveness of varicella vaccination in Canada. Vaccine. 2002, 20: 1113-25. 10.1016/S0264-410X(01)00437-6.CrossRefPubMed
27.
28.
National Advisory Committee on Immunization: Canadian Immunization guide. Ottawa, Canadian Medical Association. 1998
29.
National Health and Medical Research Council: The Australian Immunisation Handbook. Canberra, AGPS. 2000
30.
Taylor B, Miller E, Farrington CP, et al: Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet. 1999, 353: 2026-9. 10.1016/S0140-6736(99)01239-8.CrossRefPubMed
31.
Kaye JA, del Mar Melero-Montes M, Jick H: Mumps, measles and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ. 2001, 322: 460-3. 10.1136/bmj.322.7284.460.CrossRefPubMedPubMedCentral
32.
Strauss B, Bigham M: Does measles-mumps-rubella (MMR) vaccination cause inflammatory bowel disease and autism?. Can Commun Dis Rep. 2001, 27: 65-72. 10.1081/ADA-100103119.PubMed
33.
Miller D, Wadsworth J, Diamond J, Ross D: Measles vaccination and neurological events. Lancet. 1997, 349: 730-1.CrossRefPubMed
34.
Barlow WE, Davis RL, Glasser JW, et al: The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med. 2001, 345: 656-61. 10.1056/NEJMoa003077.CrossRefPubMed
35.
Virtanen M, Peltola H, Paunio M, Heinonen OP: Day-to-day reactogenecity and the healthy vaccinee effect of Measles-Mumps-Rubella Vaccination. Pediatrics. 2000, 106: e62-e68.CrossRefPubMed
36.
Davis RL, Marcuse E., Black S, et al: MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics. 1997, 100: 767-71.CrossRefPubMed
37.
Lieu T, Black SB, Ray GT, Martin KE, Shinefield HR, Weniger BG: The hidden costs of infant vaccination. Vaccine. 2000, 19: 33-41. 10.1016/S0264-410X(00)00154-7.CrossRefPubMed
38.
Netten A, Curtis L: Unit costs for health and social care 2000. Canterbury, Personal Social Services Research Unit. 2000
39.
Institute of Health Economics: A national list of provincial costs for health costs: 1997/8. Edmonton, Institute of Health Economics. 2000
40.
41.
42.
43.
Organisation for Economic Co-Operation and Development (OECD): Health Data 1998. Paris: Organisation for Economic Co-Operation and Development (OECD). 1998
44.
IMS Canada: Retail pharmacy dispensed prescription costs: Canada and provinces. Montreal: IMS Canada. 1999
45.
46.
47.
Heany DC, Sander JWAS, Shorvon SD: Comparing the cost of epilepsy across eight European countries. Epilepsy Res. 2001, 43: 89-95. 10.1016/S0920-1211(00)00168-6.CrossRef
48.
49.
Sanchez MA, Blower SM: Uncertainty and sensitivity analysis of the basic reproductive rate. Am J Epidemiol. 1997, 145: 1127-37.CrossRefPubMed
50.
@Risk: Risk Analysis and simulation add-in for Excel (version 4). New York (NY), Palisade Corporation. 2000
51.
Taracena DP, Monton JL, Cristobal P, Gonzalez F, Casas J: [The cost of measles in Spain]. An Esp Pediatr. 1983, 19: 383-8.
52.
Beutels P, van Damme P, van Casteren V, Gay NJ, De Schrijver K, Meheus A: The difficult quest for data on "vanishing" vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium). Vaccine. 2002,
53.
54.
Pelletier L, Chung P, Duclos P, Manga P, Scott J: A benefit-cost analysis of two-dose measles immunization in Canada. Vaccine. 1998, 16: 989-96. 10.1016/S0264-410X(97)00281-8.CrossRefPubMed
55.
Miller MA, Redd S, Hadler S, Hinman A: A model to estimate the potential economic benefits of measles eradication for the United States. Vaccine. 1998, 16: 1917-22. 10.1016/S0264-410X(98)00125-X.CrossRefPubMed
56.
Ekblom M, Elo O, Laurinkari J, Niemela P: Costs and benefits of measles vaccination in Finland. Scand J Soc Med. 1978, 6: 111-5.PubMed
57.
Wiedermann G, Ambrosch F: Cost-benefit calculations of vaccinations against measles and mumps in Austria. Dev Biol Stand. 1979, 43: 273-7.PubMed
58.
Bloch AB, Orenstein WA, Stetler HC, et al: Health impact of measles vaccination in the United States. Pediatrics. 1985, 76: 524-32.PubMed
59.
Carrasco JL, Lardinois R: Formula for calculating vaccine profitability. Vaccine. 1987, 5: 123-7. 10.1016/0264-410X(87)90058-2.CrossRefPubMed
60.
Moiraghi Ruggeni A, Zotti Z, Pedronetto A, Milano R, Garella D, Sachetti C: I ricoveri ispedalieri in Torino per morbillo e relative complicanze nel periodo 1973–1983: valuazioni sanitarie ed economiche, in raporto alla opportunita dell'intervento vaccinale. Bol Ist Sieroterio Milano. 1986, 65: 502-11.
61.
Hatziandreu E, Halpern NT, Brown RE, Watson GA: Cost-benefit analysis of the measles-mumps-rubella (MMR) vaccine. Arlington, VA: Center for Disease Control and Prevention. 1994
62.
Center for Disease Control and Prevention: Public attitudes towards immunization. Atlanta: Center for Disease Control and Prevention. 1977
63.
Miller C, Farrington CP, Harbert K: The epidemiology of subacute sclerosing panencephalitis in England and Wales 1970–1989. Int J Epidemiol. 1992, 21: 998-1006.CrossRefPubMed
64.
van den Hof S: Costs of measles in the Netherlands. Personal communications. 2001
65.
Cope ANK, Frank PF, Montgomery J, et al: Measles–Duval County, Florida, 1991–1992. Morb Mortal Wkly Rep. 1993, 42: 81-3.
66.
Mansoor O: Vaccine adverse events reported in New Zealand 1990–5. N Z Med J. 1997, 10: 270-2.
67.
Chavez G, Ellis A: Pediatric hospital admissions for measles. Lessons from the 1990 epidemic. West J Med. 1996, 165: 20-25.PubMedPubMedCentral
68.
Bentsi-Enchill A, Hardy M, Koch J, Duclos P: Adverse events temporally associated with vaccines – 1992 report. Can Commun Dis Rep. 1995, 21: 117-128.PubMed
69.
D'Souza RM, Campbell-Lloyd S, Isaacs D, et al: Adverse events following immunisation associated with the 1998 Australian measles control campaign. Commun Dis Intell. 2000, 24: 27-33.PubMed
70.
Department of Health: Measles Rubella (MR) Immunisation Campaign in England 1994. One Year On. London: Department of Health. 1995
71.
Patja A, Davidkin I, Kurki T, Kallio MJ, Valle M, Peltola H: Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. Pediatr Infect Dis J. 2000, 19: 1127-34.CrossRefPubMed
72.
Chen RT, Moses JM, Markowitz LE, Orenstein WA: Adverse events following measles-mumps-rubella and measles vaccinations in college students. Vaccine. 1991, 9: 297-9. 10.1016/0264-410X(91)90053-9.CrossRefPubMed
73.
Roberts RJ, Sandifer QD, Evans MR, Nolan-Farrell MZ, Davis PM: Reasons for non-uptake of measles, mumps, and rubella catch up immunisation in a measles epidemic and side effects of the vaccine. BMJ. 1995, 310: 1629-32.CrossRefPubMedPubMedCentral
74.
75.
Griffin MR, Ray WA, Mortimer EA, Fenichel GM, Schaffner W: Risk of seizures after measles-mumps-rubella immunization. Pediatrics. 1991, 88: 881-5.PubMed
76.
Okuno Y, Nakao T, Ishida N, et al: Incidence of subacute sclerosing panencephalitis following measles and measles vaccination in Japan. Int J Epidemiol. 1989, 18: 684-9.CrossRefPubMed
77.
Jonville-Bera AP, Autret E, Galy-Eyraud C, Hessel L: Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and pasteur-merieux serums and vaccines. Pediatr Infect Dis J. 1996, 15: 44-8. 10.1097/00006454-199601000-00010.CrossRefPubMed
78.
Metadata
Title
The average cost of measles cases and adverse events following vaccination in industrialised countries
Authors
Hélène Carabin
W John Edmunds
Ulla Kou
Susan van den Hof
Van Hung Nguyen
Publication date
01-12-2002
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2002
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-2-22

Other articles of this Issue 1/2002

BMC Public Health 1/2002 Go to the issue

Research article

Identification of bacteria in drinking and purified water during the monitoring of a typical water purification system

Research article

Physician perceptions of primary prevention: qualitative base for the conceptual shaping of a practice intervention tool

Research article

Reliability of race assessment based on the race of the ascendants: a cross-sectional study

Hypothesis

Is council tax valuation band a predictor of mortality?

Study protocol

Effects of chronic inflammatory bowel diseases on left ventricular structure and function: a study protocol

Research article

The new middle level health workers training in the Amhara regional state of Ethiopia: students' perspective